Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 04, 2021

SELL
$5.3 - $7.89 $22,429 - $33,390
-4,232 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$6.5 - $9.97 $27,508 - $42,193
4,232 New
4,232 $31,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.